Abstract
In 1972, Dr Hilaire Meuwissen of Albany, New York, sent some blood samples to Eloise Giblett of the Puget Sound Blood Center, Seattle, Washington, for analysis of genetic markers. One of the blood samples was from a patient with severe combined immunodeficiency disease and the other samples were from the patient’s parents Dr. Meuwissen was prepared to perform a bone marrow transplant in the patient and in preparation for the eventual necessity of documenting cell chimerism, was attempting to obtain as many genetic markers as possible to prove establishment of a bone marrow graft. Much to Dr. Giblett’s surprise, one of the enzymes, adenosine deaminase (ADA) (EC 3.5.4.4) was absent while the parents had approximately one-half normal activity. Several weeks later, Dr. Flossie Cohen of Detroit sent a blood specimen to Dr. Giblett from an additional patient with severe combined immunodeficiency disease. This patient also lacked ADA activity, while the parents had levels lower than normal. In 1973, a symposium on ADA deficiency and severe combined immunodeficiency disease was held in Albany, New York. After a careful review of laboratory and biochemical data, it was determined that 12 of 22 patients with SCID who had been tested for ADA activity in North American and Western Europe were ADA-deficient. Also in 1973, Jenkins reported finding a !Kung aborigine boy with absent red cell ADA activity but with normal function. Subsequently it was determined that the patient’s lymphocytes and fibroblasts had 10–30% of normal ADA activity. Recent reviews summarize these and additional cases [24].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
A. J. Ammann, in: “Enzyme Defects and Immune Dysfunction,” Ciba Foundation Symposium 68, p. 55, Excerpta Medica, Amsterdam.
A. J. Ammann, D. W. Wara, and T. Allen, Immunotherapy and immunopathologic studies in a patient with nucleoside phosphorylase deficiency, Clin. Immunol, and Immunopathol., 10:262–269 (1978).
A. J. Ammann, D. W. Wara, and T. Allen, Immunotherapy and immunopathologic studies in a patient with nucleoside phosphorylase deficiency, Clin. Immunol, and Immunopathol., 10:262–269 (1978).
W. D. Biggar, E. R. Giblett, R. L. Ozere, and B. D. Grove, A new form of nucleoside phosphorylase deficiency in two brothers with defective T-cell function, J. Pediatr., 92:354–357 (1978).
W. Borkowsky, A. A. Gerson, L. Shenkman, and R. Hirschhorn, Adenosine deaminase deficiency without immunodeficiency: Clinical and metabolic studies, Pediatr. Res., 14:885–889 (1980).
E. Carapella-de Luca, F. Aiuti, P. Lucarelli, L. Bruni, and C. D. Baroni, C. Imperato, D. Roos, and A. Astaldi, A patient with nucleoside phosphorylase deficiency, selective T-cell deficiency, and autoimmune hemolytic anemia, J. Pediatr., 93: 1000–1003 (1978).
D. A. Carson, J. Kaye, and J. E. Seegmiller, Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(a), Proc. Natl. Acad. Sci., U.S.A., 74:5677–5681 (1977).
D. A. Carson, J. Kaye, and D. B. Wasson, Differences in deoxy- adenosine metabolism in human and mouse lymphocytes, J. Immunol., 124:8–12 (1980).
D. A. Carson, J. Kaye, and D. B. Wasson, The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts, J. Immunol., 126: 348–352 (1981).
A. Cohen, D. Doyle, D. W. Martin, Jr., and A. J. Ammann, Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase, N. Engl. J. Med., 295:1449–1454 (1976).
A. Cohen, G. E. J. Staal, A. J. Ammann, and D. W. Martin, Jr., Orotic aciduria in two unrelated patients with inherited deficiencies of purine nucleoside phosphorylase, J. Clin. Invest., 60:491–494 (1977).
A. Cohen, R. Hirschhorn, S. D. Horowitz, A. Rubinstein, S. H. Polmar, R. Hong, and D. W. Martin, Jr., Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency, Proc. Natl. Acad. Sci., U.S.A., 75:472–476 (1978).
R. P. Creagan, J. A. Tischfield, E. A. Nichols, and F. H. Ruddle, Autosomal assignment of the gene for the form of adenosine deaminase which is deficient in patients with combined immunodeficiency syndrome, Lancet II, 1449 (1973).
N. L. Edwards, E. W. Gelfand, D. Biggar, and I. H. Fox, Partial deficiency of purine nucleoside phosphorylase: studies of purine and pyrimidine metabolism, J. Lab. Clin. Med., 91:736–749 (1978).
N. L. Edwards, D. B. Magilavy, J. T. Cassidy, and I. H. Fox, Lymphocyte Ecto-5’-nucleotidase deficiency in agammaglobulinemia, Science, 201:628–630 (1978).
N. L. Edwards, E. W. Gelfand, L. Burk, H.-M. Dosch, and I. H. Fox, Distribution of 51-nucleotidase in human lymphoid tissues, Proc. Natl. Acad. Sci., U.S.A., 76:3474–3476 (1979).
N. L. Edwards, J. T. Cassidy, and I. H. Fox, Lymphocyte 51- nucleotidase deficiency in hypogammaglobulinemia: Clinical characteristics, Clin. Immunol, and Immunopathol., 17:76–88 (1980).
E. R. Giblett, A. J. Ammann, D. W. Wara, R. Sandamn, L. K. Diamond, Nucleoside phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity, Lancet I, 1010–1013 (1975).
H. Green and T. S. Chan, Pyrimidine starvation induced by adenosine in fibroblasts and lymphoid cells: Role of adenosine deaminase, Science, 182: 836 (1973).
M. Hamet, C. Griscelli, P. Cartier, J. Ballay, C. de Bruyn, and P. Hosli, A second case of inosine phosphorylase deficiency with severe T-cell abnormalities, Adv. Exp. Med. Biol., 76A: 477–480 (1977).
L. J. Gudas, A. Cohen, B. Ullman, and D. W. Martin, Jr., Analysis of adenosine-mediated pyrimidine starvation using cultured wild-type and mutant mouse T-lymphoma cells, Somat. Cell Genet. 4:201–219 (1978).
L. J. Gudas, B. Ullman, A. Cohen, and D. W. Martin, Jr., Deoxyguanosine toxicity in a mouse T lymphoma: Relationship to purine nucleoside phosphorylase-associated immune dysfunction, Cell, 14:531–538 (1978).
M. S. Hershfield, Proposed explanation for S-adenosylhomocysteine hydrolase deficiency in purine nucleoside phosphorylase and hypoxanthineguanin phosphoribosyltransferase-deficient patients, J. Clin. Invest., 67:696–701 (1981).
R. Hirschhorn and D. W. Martin, Jr., Enzyme defects in immunodeficiency diseases, Springer Sem. in Immunopathol., 1: 299–321 (1978).
R. Hirschhorn, F. Martiniu, and F„ S. Rosen, Adenosine deaminase activity in normal tissues and tissues from a child with severe combined immunodeficiency and adenosine deaminase deficiency, Clin. Immunol, and Immunopathol., 9:287–292 (1978).
R. Hirschhorn, V. Roegner, A. Rubinstein, and P. Papageorgiou, Plasma deoxyadenosine, adenosine, and erythrocyte deoxyATP are elevated at birth in an adenosine deaminase-deficient child, J. Clin. Invest., 65:768–771 (1980).
T. Jenkins, A. R. Rabson, G. T. Nurse, A. B. Lane, and D. A. Hopkinson, Deficiency of adenosine deaminase not associated with severe combined immunodeficiency, J. Pediatr., 89:732–736 (1976).
J. M. Johnston and N. M. Kredich, Inhibition of methylation by adenosine in adenosine deaminase-inhibited, phytohemmagglutinin-stimulated human lymphocytes, J. Immunol., 123:97–103 (1979).
N. M. Kredich and M. S. Hershfield, S-adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin, Proc. Natl. Acad. Sci., U.S.A., 76:2450–2454 (1979).
N. M. Kredich and M. S. Hershfield, S-adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin, Proc. Natl. Acad. Sci., U.S.A., 76:2450–2454 (1979).
G. Marone, M. Plaut, and L. M. Lichtenstein, Characterization of a specific adenosine receptor on human lymphocytes, J. Immunol., 11:2153–2159 (1978).
W. R. A. Osborne, S.-H. Chen, E. R. Giblett, W. D. Biggar, A. J. Ammann, and C. Ronald Scott, Purine nucleoside phosphoryl ase deficiency, J. Clin. Invest., 60:741–746 (1977).
S. H. Polmar, R. C. Stern, A. L. Schwartz, E. M. Wetzler, P. A. Chase, and R. Hirschhorn, Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency, N. Engl. J. Med., 295:1337 (1976).
F. Quagliata, D. Faig, M. Conklyn, and R. Silbert, Studies on the lymphocyte 51-nucleotidase in chronic lymphocyte leukemia, infectious mononucleosis, normal subpopulations, and phyto- hemagglutinin-stimulated cells, Cancer Res., 34:3197–3203 (1974).
K. C. Rich, E. Mejias, and I. H. Fox, Purine nucleoside phosphorylase deficiency: Improved metabolic and immunologic function with erythrocyte transfusions, Med. Intell., 303:973–976 (1980).
K. C. Rich, W. J. Arnold, T. Palella, and I. H. Fox, Cellular immune deficiency with autoimmune hemolytic anemia in purine nucleoside phosphorylase deficiency, Am. J. Med., 67:172–176 (1979).
A. L. Schwartz, R. C. Stern, and S. H. Polmar, Demonstration of an adenosine receptor on human lymphocytes in vitroand its possible role in the adenosine deaminase-deficient form of severe combined immunodeficiency, Clin. Immunol, and Immuno- pathol., 9:499–505 (1978).
G. E. J. Staal, J. W. Stoop, B. J. M. Zegers, L. H. Siegenbeek von Heukelom, M. J. M. van der Vlist, S. K. Wadman, and D. W. Martin, Erythrocyte metabolism in purine nucleoside phosphorylase deficiency after enzyme replacement therapy by infusion of erythrocytes, J. Clin. Invest., 65:103–108 (1980).
J. W. Stoop, B. J. M. Zegers, G. F. M. Hendrickx, L. H. Siegenbeek van Heukelom, G. E. J. Staal, P. K. de Bree, S. K. Wadman, and R. E. Ballieux, Purine nucleoside phosphorylase deficiency associated with selective cellular immunodeficiency, N. Engl. J. Med., 296:651–655 (1977).
L. F. Thompson, G. R. Boss, H. L. Spiegelberg, A. Bianchino, and J. E. Seegmiller, Ecto-5’-nucleotidase activity in lymphoblastoid cell lines derived from heterozygotes for congenital X-linked agammaglobulinemia, J. Immunol., 125:190–193 (1980).
B. Ullman, A. Cohen, and D. W. Martin, Jr., Characterization of a cell culture model for the study of adenosine deaminase- and purine nucleoside phosphorylase-deficient immunologic disease, Cell, 9:205–211 (1976).
B. Ullman, L. J. Gudas, A. Cohen, and D. W. Martin, Jr., Deoxy- adenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease, Cell, 14:365–375 (1978).
A. R. Watson, D. I. K. Evans, H. B. Marsden, V. Miller, and P. A. Rogers, Purine nucleoside phosphorylase deficiency associated with a fatal lymphoproliferative disorder, Arch. Dis. Chil., 563–565 (1981).
A. D. B. Webster, M. North, J. Allsop, G. L. Asherson, and R. W. E. Watts, Purine metabolism in lymphocytes from patients with primary hypogammaglobulinaemia, Clin. Exp. Immunol., 31: 456–463 (1978).
R. L. Wortmann, B. S. Mitchell, N. L. Edwards, and I. H. Fox, Biochemical basis for differential deoxyadenosine toxicity to T and B lymphoblasts: Role for 51-nucleotidase, Proc. Natl. Acad. Sci., U.S.A., 76:2434–2437 (1979).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Plenum Press, New York
About this chapter
Cite this chapter
Ammann, A.J. (1985). Purine Nucleotide Imbalance in Immunodeficiency Disorders. In: de Serres, F.J. (eds) Genetic Consequences of Nucleotide Pool Imbalance. Basic Life Sciences, vol 31. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2449-2_32
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2449-2_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9488-7
Online ISBN: 978-1-4613-2449-2
eBook Packages: Springer Book Archive